[Elsevier] {Full text + Supplementary}Atrasentan in patients with IgA nephropathy (ALIGN): final 2﹞5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Mohamed2025 Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-09-11 15:09
Reward30points

Heerspink HJL et al.: Atrasentan in patients with IgA nephropathy (ALIGN): final 2﹞5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Atrasentan in patients with IgA nephropathy (ALIGN): final 2﹞5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet

Atrasentan in patients with IgA nephropathy (ALIGN): final 2﹞5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect


Also(please note: 2 links, 2 documents (supplementary material))?

https://www.thelancet.com/cms/10.1016/S0140-6736(26)00960-8/attachment/22918bab-7bf5-48b2-9d5c-8c28f653bac1/mmc1.pdf

AND this:

https://www.thelancet.com/cms/10.1016/S0140-6736(26)00960-8/attachment/9780e1e6-7469-4fb0-9d91-386fc3536068/mmc2.pdf

supplementary material to:

Atrasentan in patients with IgA nephropathy (ALIGN): final 2﹞5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Heerspink HJL et al.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    140


Return to the list